Pramiracetam
A lipophilic racetam derivative marketed as a potent nootropic, dosed in the low milligram range. Human data is limited to small trials in elderly cognitive impairment and post-traumatic memory deficits; broad cognitive-enhancement claims in healthy users rest on anecdote.
01 Overview
Pramiracetam is a fat-soluble analogue of piracetam developed in the 1970s. It is claimed to enhance memory and attention, and unlike piracetam is active at low oral doses. The few published human studies examined elderly subjects and men with traumatic brain injury rather than healthy adults.
It is unscheduled in most countries and sold as a research chemical or supplement. Because it does not appreciably alter mood or produce a subjective 'high', users often report difficulty perceiving any effect, which complicates self-assessment of efficacy.
02 Mechanism
Thought to enhance high-affinity choline uptake in the hippocampus and modulate cerebral blood flow; the precise mechanism and whether it engages glutamatergic systems remain uncertain.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 100–200 mg | Oral | Fat-soluble; often taken with a source of dietary fat. |
| Common | 300–600 mg/day | Oral | Frequently split into 2-3 doses. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Improved memory in impaired populationsSmall trials reported memory gains in elderly and TBI patients; effect in healthy users is unestablished. | Modest | Clinical | |
| Increased focus and mental clarityCommonly reported by users but not demonstrated in controlled healthy-subject trials. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HeadacheA frequently reported racetam side effect, often attributed to increased acetylcholine turnover. | Mild | Common | Anecdotal | |
| Irritability and restlessnessSome users report agitation or difficulty relaxing. | Mild | Uncommon | Anecdotal |